IP Library Granted Patent US 10,668,088
Granted Patent B2
US 10,668,088 · App. 15/541,793 · Granted Jun 2, 2020

Combination of 25-hydroxyvitamin D and antioxidants/anti-inflammatories for human nutraceuticals

Inventors: Shuen Ei Chen (Kaiseraugst, CH); Thau Kiong Chung (Kaiseraugst, CH); Daniel Raederstorff (Kaiseraugst, CH); Wolfgang Schalch (Kaiseraugst, CH)
Assignee: DSM IP ASSETS B.V.
A61K31/593A23D7/0053A23K20/158A23K20/174A23K20/179A23K20/30A23K50/75A23L33/105A23L33/15A23L33/155A23L33/16A61K31/01A61K31/015A61K31/045A61K31/047A61K31/05A61K31/065A61K31/122A61K31/197A61K31/355A61K31/375A61K31/4188A61K31/455A61K31/519A61K31/525A61K31/592A61K31/675A61K33/04A61K33/30A61K33/32A61K33/34A61K45/06A61P3/04A61P3/06A61P3/10A61P9/00A61P15/08A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,088
App. No.
15/541,793
Granted
Jun 2, 2020
Kind
B2
Abstract

This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in humans connected with polycystic ovarian 5 syndrome and cardiovascular diseases. Pharmaceuticals, nutraceuticals and food supplements containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.

Claims (3)

1. A method of ameliorating a symptom of polycystic ovary syndrome in a vitamin replete person at risk of developing the syndrome, comprising:

administering to a vitamin replete person who has polycystic ovary syndrome or who is at risk of developing polycystic ovary syndrome an effective amount of a daily dosage combination comprising:

1 μg to 50 μg 25-hydroxyvitamin D3, 1-1000 mg/day Vitamin C, 5-750 mg Vitamin E, and one or more carotenoids selected from the group consisting of: 1-150 mg astaxanthin, 1-100 mg β-cryptoxanthin, 1-100 mg beta-carotene, 1-100 mg lutein, 1-60 mg zeaxanthin and not more than 30 mg canthaxanthin, wherein the daily dosage combination does not include lycopene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2022
From: BELAJ INNOVATIONS, LLC
To: MARY KAY INC.
Reel/Frame 062144/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2017
From: CHEN, SHUEN EI; CHUNG, THAU KIONG; RAEDERSTORFF, DANIEL; SCHALCH, WOLFGANG
To: DSM IP ASSETS B.V.
Reel/Frame 044031/0149 →
Priority Claims (2)
EP 15166937 · May 8, 2015 · regional
EP 15172721 · Jun 18, 2015 · regional
Continuity (2)
Provisional Application 62103769 · Jan 15, 2015
Related Publication 20190015429A1 · Jan 17, 2019